Health Care & Life Sciences » Biotechnology | Panacos Pharmaceuticals Inc.

Panacos Pharmaceuticals Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2003
2004
2005
2006
2007
Net Income before Extraordinaries
4,508.00
12,038.30
59,078.00
38,110.00
37,459.00
Depreciation, Depletion & Amortization
78.40
112.00
628.00
751.00
538.00
Other Funds
-
-
-
31.00
-
Funds from Operations
4,370.50
11,206.70
21,298.00
29,586.00
31,903.00
Changes in Working Capital
419.10
983.50
348.00
44.00
868.00
Net Operating Cash Flow
3,951.40
10,223.20
21,646.00
29,630.00
31,035.00
Capital Expenditures
8.10
76.40
150.00
519.00
48.00
Sale of Fixed Assets & Businesses
-
-
6.00
-
-
Purchase/Sale of Investments
-
-
-
25,715.00
15,198.00
Net Investing Cash Flow
8.10
76.40
406.00
26,183.00
15,150.00
Issuance/Reduction of Debt, Net
2,715.30
184.40
1,160.00
148.00
19,591.00
Net Financing Cash Flow
2,728.80
14,702.40
103,499.00
1,815.00
20,610.00
Net Change in Cash
1,230.80
4,402.80
82,259.00
53,998.00
4,725.00
Free Cash Flow
3,959.60
10,299.60
21,796.00
30,149.00
31,083.00
Other Sources
-
-
550.00
51.00
-
Change in Capital Stock
13.50
14,886.80
104,659.00
1,698.00
1,019.00
Miscellaneous Funds
0.00
0.00
-
0.00
-

About Panacos Pharmaceuticals

View Profile
Address
134 Coolidge Avenue
Watertown Massachusetts 02472
United States
Employees -
Website http://www.panacos.com
Updated 07/08/2019
Panacos Pharmaceuticals, Inc. is a development stage company engaged in the discovery and development of small-molecule oral drug which is designed to treat Human Immunodeficiency Virus and other major human viral diseases. Its primary product is Bevirimat which is an oral human immunodeficiency virus which provides a novel mechanism of action called maturation inhibition. The company was founded by Graham Allaway in March 2005 and is headquartered in Watertown, MA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.